These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
3. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
4. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
5. US policy may encourage counterfeit drugs. Bouchie A Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826 [No Abstract] [Full Text] [Related]
6. Balancing innovation, access, and profits--market exclusivity for biologics. Engelberg AB; Kesselheim AS; Avorn J N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525 [No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: cost savings. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446 [No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: business practices. Steiner DJ Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889 [No Abstract] [Full Text] [Related]
9. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars. Gitter DM Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759 [No Abstract] [Full Text] [Related]
10. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
11. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice? Shah S; Silva MA; Malloy MJ Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880 [No Abstract] [Full Text] [Related]
12. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
13. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
14. India remains on US trade "priority watch list" for failing to uphold international drug company patents. Arie S BMJ; 2013 May; 346():f2949. PubMed ID: 23657189 [No Abstract] [Full Text] [Related]
15. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
16. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry. Brockmeier MS Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564 [No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
18. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]